Breast Cancer

Anti-HER2 Combo Active in Metastatic Breast Cancer

News | April 23, 2014 | HER2-Positive Breast Cancer, Breast Cancer

Dual HER2-targeted treatment with T-DM1 and pertuzumab resulted in positive antitumor activity in patients with HER2-positive, locally advanced or metastatic breast cancer, with an overall response rate of 41%.

Blood Test Predicts Breast Cancer Recurrence

Anna Azvolinsky, PhD

News | April 18, 2014 | Breast Cancer

By Anna Azvolinsky, PhD

A new pilot study demonstrates the ability of a blood-based test to detect metastatic breast cancer recurrence with high sensitivity and specificity.

HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review

Ursa Brown-Glaberman, MD

Zoneddy Dayao, MD

Melanie Royce, MD, PhD

Review Article | April 15, 2014 | Oncology Journal, Breast Cancer, HER2-Positive Breast Cancer

By Ursa Brown-Glaberman, MD, Zoneddy Dayao, MD, and Melanie Royce, MD, PhD

This review discusses the treatment of primary, nonmetastatic HER2-positive breast cancer in the adjuvant and neoadjuvant settings—settings in which tremendous progress has been made.

HER2 Targeting in Early Breast Cancer: More Options and More Questions

Barry C. Lembersky, MD

Priya Rastogi, MD

April 15, 2014 | Oncology Journal, Breast Cancer, HER2-Positive Breast Cancer

By Barry C. Lembersky, MD and Priya Rastogi, MD

Therapies targeting HER2 have revolutionized the treatment of breast cancer. Trastuzumab is the foundation of treatment for women with HER2-positive breast cancer. The challenge ahead is to develop predictors that can identify patients for whom trastuzumab alone will be sufficient.

HER2-Positive Breast Cancer: The Story Goes On

Mary D. Chamberlin, MD

Peter A. Kaufman, MD

April 15, 2014 | Oncology Journal, Breast Cancer, HER2-Positive Breast Cancer

By Mary D. Chamberlin, MD and Peter A. Kaufman, MD

It will be critically important to await the longer-term DFS and OS results from the neoadjuvant studies, as well as the adjuvant studies evaluating dual HER2 blockade, prior to these approaches truly becoming the standard of care.

Loss of PTEN in Breast Cancer Led to PI3K Inhibitor Resistance

Anna Azvolinsky, PhD

News | April 10, 2014 | AACR 2014, Breast Cancer

By Anna Azvolinsky, PhD

Loss of the tumor suppressor PTEN was found to be a frequent mechanism of resistance to treatment with the PI3K-alpha inhibitor BYL719 in women with breast cancer.

CDK Inhibitors Show Impressive Activity in Advanced Breast Cancer

Anna Azvolinsky, PhD

News | April 08, 2014 | AACR 2014, Breast Cancer

By Anna Azvolinsky, PhD

Two early trials studying CDK inhibitors in metastatic breast cancer have shown impressive activity in HR-positive disease, according to data presented at the AACR annual meeting.

Pages

Videos
Podcasts

Nine of Ten Women Cannot Quantify Lifetime Breast Cancer Risk
Leah Lawrence
News | September 10, 2013 | ASCO 2013 Breast Cancer Symposium, Breast Cancer
By Leah Lawrence
More than 90% of women about to undergo a mammography were unable to accurately quantify their risk for breast cancer, either over- or underestimating their risk, according to the results of a large-scale survey presented at the ASCO Breast Cancer Symposium 2013.
Batch MRI Breast Cancer Screening Possibility With Accelerated Protocol
Leah Lawrence
News | September 09, 2013 | ASCO 2013 Breast Cancer Symposium, Breast Cancer, Screening
By Leah Lawrence
Expert radiologists were able to screen magnetic resonance images and rule out breast cancer diagnosis with a negative predictive value of about 99% using an abridged breast MRI protocol in a single-center study presented Saturday at the ASCO Breast Cancer Symposium 2013.
What to Look for at This Year’s ASCO Breast Cancer Symposium
Tari A. King, MD
September 14, 2012 | ASCO 2012 Breast Cancer Symposium, Breast Cancer
By Tari A. King, MD
In this video, Tari A. King, MD, of the Memorial Sloan-Kettering Cancer Center, discusses what to look for at this year’s ASCO Breast Cancer Symposium.
ASCO: New Research on HER2-Positive Breast Cancer
Luca Gianni, MD
June 13, 2011 | ASCO 2011 Breast Cancer, Breast Cancer, ASCO 2011, HER2-Positive Breast Cancer, Triple-Negative Breast Cancer
By Luca Gianni, MD
Dr. Gianni has been involved with new drug therapies in medical oncology for some time, and in this interview he discusses the changing use of breast cancer treatments, neoadjuvant regimens, and research and developments on HER2+ breast cancer.

Circling Back: Duration of Adjuvant Endocrine Therapy for Breast Cancer
Nancy E. Davidson, MD
Rachel C. Jankowitz, MD
January 16, 2014 | Oncology Journal, Breast Cancer
By Nancy E. Davidson, MD and Rachel C. Jankowitz, MD
In this Circling Back feature, authors of the review article “Adjuvant Endocrine Therapy for Breast Cancer: How Long Is Long Enough?” discuss some of the especially interesting points made in the commentaries.
Sentinel Lymph Node Surgery for Breast Cancer
Kelly K. Hunt, MD
October 25, 2013 | Breast Cancer
By Kelly K. Hunt, MD
A recent prospective trial showed sentinel lymph node surgery has a clinically significant high false negative rate in breast cancer patients with node-positive disease receiving neoadjuvant chemotherapy. In this interview we discuss surgical techniques that detect breast cancer in lymph nodes.
Identifying Indolent vs Potentially Aggressive DCIS, More Research Needed
Susan K. Boolbol, MD
Conference Report | September 07, 2013 | ASCO 2013 Breast Cancer Symposium, Breast Cancer
By Susan K. Boolbol, MD
As part of our coverage for the ASCO Breast Cancer Symposium 2013, we spoke with Dr. Susan K. Boolbol, chief of the division of breast surgery at the Appel-Venet Comprehensive Breast Service at Beth Israel Medical Center in New York City, who is chairing a general session panel discussion on the overdiagnosis of breast cancer.
ASCO: Neoadjuvant Therapy Options and Clinical Trials in Breast Cancer
Angela DeMichele, MD
May 29, 2013 | Breast Cancer, ASCO 2013 Breast Cancer
By Angela DeMichele, MD
Ahead of the ASCO 2013 meeting we discuss neoadjuvant therapy options and clinical trials in breast cancer, as well as the opportunities for targeted therapies in post-neoadjuvant trials.

Breast Cancer

Topics

Breast Cancer

Pages

Oncology Current Issue

SearchMedica Rx

Register Today — It's Free!

UBM Medica Network

About UBM Medica

Breast Cancer

Topics

Breast Cancer

Pages

Already Registered? Login Now:

Register Today - It's Free!

Oncology Current Issue

SearchMedica Rx

Register Today — It's Free!

UBM Medica Network

About UBM Medica

Find Us On...